

MYLAN LABORATORIES LIMITED F-4 & F-12, Malegaon MIDC, Sinnar, Nashik - 422 113, Maharashtra, India.

CERTIFICATE OF ANALYSIS

Name of the Product: MyHEP ALL (Sofosbuvir and Velpatasvir Film-coated Tablets 400 mg / 100 mg)			
Batch No.	3108120	A.R. No.	MLNFP19011713
Mfg. Date	Nov-2019	Market	Emerging
Exp. Date	Oct-2021	Batch Size	2,50,000 Tablets
Ref. Spec No.	FPSSFV195R-06	Date of Analysis	Dec 05, 2019

Identification A. By HPLC	Light green to green colored, modified capsule shaped biconvex beveled edge film coated tablet debossed with M on one side and SFV on the other side. The retention time of the Sofosbuvir and Velpatasvir peaks in the chromatogram of the test preparation	Light green colored, modified capsule shaped biconvex beveled edge film coated tablet debossed with M on one side and SFV on the other side. The retention time of the Sofosbuvir and Velpatasvir peaks in the chromatogram of
	and Velpatasvir peaks in the	
A. By HPLC	and Velpatasvir peaks in the	
	should corresponds to that in the chromatogram of the standard preparation as obtained in the test "Assay (By HPLC)".	the test preparation corresponds to that in the chromatogram of the standard preparation as obtained in the test "Assay (By HPLC)".
B. By HPLC	Compare the spectrums of the	Compare the spectrums of the Sofosbuvir
(With PDA detector)	Sofosbuvir and Velpatasvir peaks from the test solution chromatogram with that of the standard solution chromatogram from the PDA data. The test spectrum should match with that of standard spectrum due to Sofosbuvir and Velpatasvir peaks.	and Velpatasvir peaks from the test solution chromatogram with that of the standard solution chromatogram from the PDA data. The test spectrum matches with that of standard spectrum due to Sofosbuvir and Velpatasvir peaks
Dissolution (By HPLC)		
Sofosbuvir 400 mg	Complies with Ph. Eur. General Chapter 2.9.3 Not less than 80% (Q = 75%) of the labeled amount of Sofosbuvir, C 22 H 29 FN 3 O 9 P should be dissolved in 30 minutes.	(Tab-1): 94 % (Tab-2): 96 % (Tab-3): 95 % (Tab-4): 96 % (Tab-5): 96 % (Tab-6): 96 % Min: 94 % Max: 96 % Avg: 96 % RSD:1.1%
Velpatasvir 100 mg	Complies with Ph. Eur. General Chapter 2.9.3 Not less than 80% (Q = 75%) of the labeled amount of Velpatasvir, C 49H 54N 80 8 should be dissolved in 30 minutes.	(Tab-1): 91 % (Tab-2): 94 % (Tab-3): 93 % (Tab-4): 94 % (Tab-5): 94 % (Tab-6): 93 %
	(With PDA detector) Dissolution (By HPLC)	(With PDA detector) Sofosbuvir and Velpatasvir peaks from the test solution chromatogram with that of the standard solution chromatogram from the PDA data. The test spectrum should match with that of standard spectrum due to Sofosbuvir and Velpatasvir peaks. Dissolution (By HPLC) Sofosbuvir 400 mg Complies with Ph. Eur. General Chapter 2.9.3 Not less than 80% (Q = 75%) of the labeled amount of Sofosbuvir, C 22 H 29 FN 3 O 9 P should be dissolved in 30 minutes. Velpatasvir 100 mg Complies with Ph. Eur. General Chapter 2.9.3 Not less than 80% (Q = 75%) of the labeled amount of Velpatasvir, C 49 H 54 N 8 O 8 should

Dronard Dry Dravin Chada	Appr	round Du . Do	iondro Adoutor
Prepared By : Pravin.Ghode			jendra.Adavkar
Prepared On : Dec 12 2019 5:15PM	Appr	oved On : De	ec 12 2019 5:27PM
Printed by: Pravin.Ghode	Printed on: Dec 12 2019 5:49	PM	Copy No.: 1
			Page No.: 1 of 3
Note: This document has been ge	nerated electronically and is valid	without sig	gnature.
CNo: C80000012717			-
Plot No. 564/A/22, Road No. 92, Jubliee	Hills, Hyderahad - 500 034, Telangana	India	
1oo. oo t22, .toud 110. o2, oublied	· · · · · · · · · · · · · · · · · · ·	.,	



MYLAN LABORATORIES LIMITED F-4 & F-12, Malegaon MIDC, Sinnar, Nashik - 422 113, Maharashtra, India.

CERTIFICATE OF ANALYSIS

Name of the Product: MyHEP ALL (Sofosbuvir and Velpatasvir Film-coated Tablets 400 mg / 100 mg)			
Batch No.	3108120	A.R. No.	MLNFP19011713
Mfg. Date	Nov-2019	Market	Emerging
Exp. Date	Oct-2021	Batch Size	2,50,000 Tablets
Ref. Spec No.	FPSSFV195R-06	Date of Analysis	Dec 05, 2019

S. No.	TEST	SPECIFICATION	RESULT
			Min : 91 %
			Max : 94 %
			Avg : 93 %
			RSD:1.0%
4	Uniformity of dosage units (By		
	Content Uniformity)		
4.1	Sofosbuvir 400 mg	Complies with Ph. Eur. General	
		Chapter 2.9.40	Sample-1 : 98.2 %
		The Acceptance Value (AV) should be	Sample-2 : 100.9 %
		not more than 15.0.	Sample-3 : 99.7 %
			Sample-4 : 99.9 %
			Sample-5 : 99.1 %
			Sample-6 : 98.4 %
			Sample-7 : 101.4 %
			Sample-8 : 100.0 %
			Sample-9 : 99.8 %
			Sample-10 : 99.2 %
			Average : 99.7 %
			AV:2.4
4.2	Velpatasvir 100 mg	Complies with Ph. Eur. General	
		Chapter 2.9.40	Sample-1 : 95.3 %
		The Acceptance Value (AV) should be	Sample-2 : 98.2 %
		not more than 15.0.	Sample-3 : 96.8 %
			Sample-4: 96.6 %
			Sample-5 : 96.1 %
			Sample-6 : 95.2 %
			Sample-7 : 98.4 %
			Sample-8 : 97.0 %
			Sample-9: 96.6 %
			Sample-10 : 96.1 %
			Average : 96.6 %
_			AV:4.4
5	Assay (By HPLC)		
5.1	Sofosbuvir 400 mg	Not less than 360.00 mg and not more	
		than 440.00 mg of Sofosbuvir, C	In mg : 400.78 mg
		₂₂ H ₂₉ FN	In %:100.2% w/w
		₃ O ₉ P	
		(90.0% w/w - 110.0% w/w of labeled	
		amount of Sofosbuvir)	
5.2	Velpatasvir 100 mg	Not less than 90.00 mg and not more	

Remarks: APPROVED (Sample Conform	ns to above Specification)			
Prepared By : Pravin.Ghode		Approved By : R	ajendra.Adavkar	
Prepared On : Dec 12 2019 5:15PM	A	Approved On : Dec 12 2019 5:27PM		
Printed by: Pravin.Ghode	Printed on: Dec 12 2019 5	5:49PM	Copy No.: 1	
			Page No.: 2 of 3	
Note : This document has been ger	nerated electronically and is va	alid without s	ignature.	
CNo: C80000012717				
Plot No. 564/A/22, Road No. 92, Jubliee	Hills, Hyderabad - 500 034, Telang	ana, India		
Tel: 91-40-30866666, 23550543, Fax: 308	866699			



MYLAN LABORATORIES LIMITED F-4 & F-12, Malegaon MIDC, Sinnar, Nashik - 422 113, Maharashtra, India.

CERTIFICATE OF ANALYSIS

Name of the Product: MyHEP ALL (Sofosbuvir and Velpatasvir Film-coated Tablets 400 mg / 100 mg)			
Batch No.	3108120	A.R. No.	MLNFP19011713
Mfg. Date	Nov-2019	Market	Emerging
Exp. Date	Oct-2021	Batch Size	2,50,000 Tablets
Ref. Spec No.	FPSSFV195R-06	Date of Analysis	Dec 05, 2019

S. No.	TEST	SPECIFICATION	RESULT
		than 110.00 mg of Velpatasvir, C	In mg : 97.53 mg
		₄₉ H ₅₄ N	In %:97.5% w/w
		₈ O ₈	
		(90.0% w/w – 110.0% w/w of labeled	
		amount of Velpatasvir)	
6	Related Substances (By HPLC)		
6.1	A.Velpatasvir impurities:		
6.1.1	a.Amine free base	Not more than 1.0% w/w	Not Detected
6.1.2	b.Lactone impurity	Not more than 1.0% w/w	0.033 % w/w
6.1.3	c. Any unknown impurity	Not more than 0.5% w/w	0.213 % w/w
6.2	B.Sofosbuvir impurities:		
6.2.1	a.Fluoro uridine impurity	Not more than 0.5% w/w	Not Detected
6.2.2	b. Any unknown impurity	Not more than 0.5% w/w	0.029 % w/w
6.3	C.Total impurities (A + B)	Not more than 3.5% w/w	0.354 % w/w
7	Residual solvents (By GC)		
7.1	Ethanol	Not more than 5000 ppm	282 ppm
8	Water (By KF)	Not more than 5.5% w/w	2.43 % w/w

Storage: Do not store above 30 °C, store in original container.

Remarks: APPROVED (Sample Conforms to above Specification) Prepared By: Pravin.Ghode Approved By: Rajendra.Adavkar Approved On : Dec 12 2019 5:27PM Prepared On : Dec 12 2019 5:15PM Printed on: Dec 12 2019 5:49PM Printed by: Pravin.Ghode Copy No.: 1 Page No.: 3 of 3 Note: This document has been generated electronically and is valid without signature. CNo: C80000012717

Plot No. 564/A/22, Road No. 92, Jubliee Hills, Hyderabad - 500 034, Telangana, India

Tel: 91-40-30866666, 23550543, Fax: 30866699